This article discusses the corporate mission, strategies, organizational leadership, and portfolio that PharmAthene (PIP) and Theraclone Sciences will create by merging. It explains why the combination will be synergistic and increase shareholder value. Because Theraclone Sciences is a privately-held company, I give more space to its programs: I explain the importance of monoclonal antibody therapeutics and the virtues of Thereaclone's I-STAR-its engine for discovering and developing promising monoclonal antibodies . I also provide an unorthodox rationale for putting a high priority on searching for better ways of dealing with Human Cytomegalovirus (CMV) infection.
I encourage you to work through any parts of this journey that may push you beyond your comfort zone: e.g., explanations of immunological concepts, the...
Only subscribers can access this article, which is part of the PRO research library covering 3,775 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: